The solution is to automate reading of skin allergic tests. Our SkinSENSE™ system with HYBRID II™ head for multispectral imaging introduces a new quality in allergology.
Allergy is currently the most serious health problem, it is already pandemic proportions. In highly developed countries. The population of allergies in Europe is estimated at around 150 million people. The increase in the incidence of various types of allergies in highly industrialized countries has been uninterruptedly for over 50 years, the worst of which is that already now, the rate of hypersensitivity to one or more allergens / haptens among school-age children has come close to the magic limit of ok 50%.
Even in the most developed countries, access to allergy specialists is difficult. The European Academy of Allergology and Clinical Immunology (EAACI) predicts that over the next 15 years, more than half of Europeans will suffer from some kind of allergy, and the number of specialists does not increase proportionally to the number of patients.
The solution is to automate the reading of skin allergy tests. Our SkinSense ™ system with the HYBRID II ™ transducer for hyperspectral imaging brings a new dimension to allergology by:
– the use of a unique sensor system,
– the use of Artificial Intelligence accurately estimating the severity of allergies
– reducing the risk of allergy misdiagnosis:
replacing the eye measurement, performed with a ruler or a measure, with an algorithmic evaluation based on the measured physical values - inflammatory field size and temperature – meeting the requirements of Evidence-Based Medicine.
The SkinSense ™ System is 100% compatible with all skin test kits available on the market, both for the “Prick Tests” and “Patch Tests”.
The allergy medical diagnosis market is estimated at $ 5.6 billion (2017), with a CAGR of 9-14% (Compound Annual Growth Rate). Medical statistics show that in:
– around 20 million allergy tests are performed in the EU every year,
– USA approx. 25 million,
– Asia, approx. 24 million.
FaceCOV™ will probably be the world’s first registered medical device to allow remote temperature measurement from a distance.
The number of people suffering from COVID-19 has exceeded 40 million. Over a million people died. According to the World Health Organization, 88.1% of people with COVID-19 developed high fever. This most common symptom is measured incorrectly by most systems on the market. Most of the currently available systems do not meet the basic metrological requirements (very large measurement errors).
It is extremely important to implement screening systems that will accurately and in accordance with medical knowledge check the temperature of the human body – both in the COVID-19 pandemic and in future epidemics that occur every few to several years. That is why it is so important to implement solutions that with great certainty (medical device standard) will determine the symptoms indicating the development of the disease.
FACE-COV will probably be the first registered medical device in the world that allows remote temperature measurement from a long distance. The medical characteristics of the device will ensure high quality of measurement and avoiding errors. Application at airports or stations, where people detained due to incorrectly measured temperature may miss the plane or train and charge the operator with compensation, will help avoiding consequences .
Temperature measurement is the only way to achieve massive epidemiological monitoring. All airports, stations, hospitals and strategic facilities should be equipped with appropriate systems to prevent the entry of people with COVID-19 symptoms.
The recipients of the solution will be, in the first place, managers of public facilities, especially those of high strategic importance. Thanks to security and certificates, it will be possible to offer the system to places where the use of competitive solutions is impossible.
The InfraSKIN™ device will be strictly professional and will be aimed at dermatologists and oncologists. Its innovation will be based on LWIR band measurement, allowing to assess the rate of metabolism in the examined nevus – increased metabolism in the skin nevus indicates pathological cells.
Melanoma is the third most common type of cancer, after breast and prostate cancer.
Melanoma kills more people than any other skin cancer combined. The mortality rate ranges from 2.9% (Australian Institute of Health and Welfare 2020) to 6.8% (Siegel, Miller, and Jemal 2020)
Currently, the basic method of detecting melanoma at an early stage is a medical consultation using a dermatoscope. In the case of people with a large number of moles on the skin, such a visit takes up to 90 minutes. Therefore, new diagnostic tools are needed to distinguish malignant lesions from common moles at an early stage. Importantly, the five-year survival rate for melanoma detected in the earliest stages is about 97%, and drops to about 14% if it is only detected in the advanced stages.
This example illustrates well why the InfraSkin ™ system is so important in terms of epidemiology and skin cancer mortality. Early detection can have a huge positive impact on the results of successful treatment (American Cancer Society 2018; Guy et al. 2015)
The InfraSkin device will be strictly professional and will be directed to specialist dermatologists and oncologists. Its innovation will consist in measuring in the LWIR band, making it possible to assess the rate of metabolism in the test mark – increased metabolism in a skin mark indicates pathological cells.
The main hardware solutions (transducer – scanning head) are common to all three solutions. The system will be developed after the implementation of the Face-COV and SkinSense systems on the market.